TABLE 3

Univariate Analysis and Multivariable Analysis of OS and rPFS in T-Pretreated Patients

	Univariate analysis				Multivariable analysis
	OS		rPFS		OS		rPFS
Subgroup	HR	P	HR	P	HR	P	HR	P
Age: >70 y	0.97 (0.55–1.72)	0.926	1.00 (0.62–1.61)	0.985	NA	NA	NA	NA
Karnofsky performance status: ≤80	2.94 (1.43–6.07)	0.003	1.56 (0.94–2.60)	0.088	2.71 (1.22–6.03)	0.015	1.41 (0.81–2.46)	0.221
Baseline PSA: >60 ng/mL	2.59 (1.28–5.26)	0.008	1.43 (0.86–2.39)	0.173	0.96 (0.44–2.10)	0.924	0.61 (0.32–1.15)	0.125
Time from diagnosis to first ¹⁷⁷Lu-PRLT treatment: >5 y	0.70 (0.40–1.23)	0.217	0.54 (0.33–0.88)	0.013	NA	NA	0.49 (0.30–0.82)	0.006
Cumulative administered activity: >16 GBq	0.32 (0.18–0.58)	<0.001	0.81 (0.50–1.30)	0.375	0.37 (0.20–0.69)	0.002	NA	NA
Bone metastases: yes	11.77 (1.61–86.20)	0.015	2.29 (0.98–5.34)	0.057	3.03 (0.38–24.15)	0.295	1.13 (0.44–2.88)	0.801
Visceral metastases: yes	2.71 (1.50–4.89)	0.001	1.55 (0.91–2.64)	0.110	1.72 (0.92–3.24)	0.090	0.97 (0.53–1.76)	0.908
Baseline hemoglobin: ≤7.5 mmol/L	4.61 (2.04–10.39)	<0.001	2.56 (1.45–4.50)	0.001	2.76 (1.11–6.89)	0.029	2.59 (1.26–5.33)	0.010
Baseline ALP: ≥220 U/L	1.84 (1.02–3.33)	0.043	2.21 (1.33–3.65)	0.002	1.20 (0.64–2.27)	0.570	2.00 (1.14–3.50)	0.015